
# Life Science Deals Hot Topics in 2018


Jennifer L. Porter – Pepper Hamilton LLP Aparna Nemlekar – Pepper Hamilton LLP Thomas M. Gallagher – Pepper Hamilton LLP




## **Audio**




## **Audio**




## Q&A



## **Download PPT Slides**



## **Download PPT Slides**



## **Capabilities**

#### Best Lawyers

More than 65 lawyers listed, including 9 as Lawyer of the Year

lawyers highly rated by Super Lawyers and Rising Stars

#### SERVICES

BUSINESS
GOVERNMENT REGULATION
HEALTH SCIENCES
INTELLECTUAL PROPERTY
INTERNATIONAL
LITIGATION

#### **INDUSTRIES**

CONSTRUCTION

**ENERGY** 

FINANCIAL

FOOD AND BEVERAGE

**HEALTH SCIENCES** 

HIGHER EDUCATION

INVESTMENT FUNDS

LIFE SCIENCES

MEDIA, COMMUNICATIONS AND

**ENTERTAINMENT** 

NONPROFIT ORGANIZATIONS AND

**FOUNDATIONS** 

PHARMACEUTICAL AND MEDICAL DEVICE

RETAIL

**TECHNOLOGY** 

TRANSPORTATION



#### Locations





We will be starting at 12pm ET. There is currently no audio until we start.



# Email dolanb@pepperlaw.com for a CLE form if interested



# Thomas M. Gallagher

Partner | Health Sciences Department 215.981.4068 gallaghert@pepperlaw.com

- Chair of the Executive Committee of Pepper Hamilton LLP
- Represents clients in white collar criminal matters, corporate investigations and complex civil litigation
- National practice is focused on representing entities facing government investigations particularly focused in the health care industry. Also represents businesses and individuals facing investigation by federal and state law enforcement authorities, government regulatory agencies and congressional committees.
- Frequent author and regular speaker at seminars and conferences.





### Jennifer L. Porter

Partner | Health Sciences Department 215.981.4339 porterj@pepperlaw.com

Advises public and private pharmaceutical, biotechnology, and medical device companies in a broad range of matters, including U.S. and international mergers and acquisitions, joint ventures, divestitures, capital markets transactions, Securities Exchange Act reporting, corporate governance, licensing and collaboration transactions and other strategic transactions

Counsels clients in strategic transactions, disclosure and governance issues and regularly handles complex commercial transactions, including strategic alliances, technology licenses and acquisitions, supply distribution and manufacturing agreements.





## **Aparna Nemlekar**

Associate and Registered Patent Attorney | Health Sciences Department 412,454,5021

nemlekara@pepperlaw.com

 Works with well-established and nascent companies, universities, and independent inventors to identify and protect their intellectual property

Concentrates her practice in strategic patent and trademark preparation and prosecution of domestic and international applications, preparation of patentability and clearance opinions, trademark clearances, life science transactions, and other intellectual property related counseling

Technology practice includes work in the molecular biology, nutritional supplement, pharmaceutical, organic chemistry, diagnostic, vaccine, immunology, medical, mechanical, medical device, software and business method areas.




### **Overview**

- Life Sciences Deals in 2018
  - Year-to-date performance
  - Trends
  - Structuring Considerations
- Intellectual Property Diligence
  - Importance of IP
  - Seller Considerations
  - Purchaser Considerations
- Mitigating Risks



## 2018 – The Deal Landscape

- Deal market growing in 2018
  - Top 10 2018 deals valued over \$170 billion
  - Value and Volume up on Q2 2018





## 2018 – The Deal Landscape

- What are the drivers?
  - Tax reform & favorable repatriation rate
  - Patent cliff
  - Price Pressure
  - Technology Entrants



## 2018 - The Deal Landscape - Trends

- Divestitures
- Consolidation
- Growth areas: Oncology & Specialty Therapies
- Customer-Centric Products/Marketing



# **Transaction Structuring Considerations**

#### License

- Allows separate transactions for various fields/territories to maximize value
- Easier for licensor to regain control after termination of a license (compared to exercising reversion rights over transferred IP)
- Allows licensor a mechanism to control conduct of licensee
- Parties connected in the public eye

#### Collaborate

- Risk (and reward) shared with partner
- Obtain a stake in asset with low up-front investment
- Parties connected in the public eye

#### Buy/Sell

 Can be a complete exit for the seller and maximum control for the buyer



## **Transaction Structuring Considerations**

- Consideration Structure
  - Upfront
  - Deferred 75% of Life Sciences M&A
     Transactions have a deferred component
    - Milestones
    - Royalties
    - Sublicense Revenue/ Sales Proceeds



### **Deferred Consideration Pros and Cons**

#### Pros:

- Can bridge the valuation gap
- A form a financing for the buyer
- Allows seller to participate in upside

#### ► Cons:

- Increased complexity, especially if public company
- Increased litigation risk
- Seller is exposed to buyer's credit risk



### **Deferred Consideration Pros and Cons**

- Most Litigated Issue = "Commercially Reasonable Efforts"
  - Typically focused on buyer's usual efforts
  - "Those reasonable, diligent, good faith efforts consistent with usual practices of the Buyer in respect of researching, developing, or commercializing its own compound or product, or one to which it has rights, that is of similar scientific and commercial potential, and is at a similar stage in its development, in each case taking into account all relevant factors including issues of safety and efficacy, the patent, and other proprietary position of the Compound or a Product, the likelihood of Regulatory Approval, the then-current competitive environment, the profitability and commercial potential of the Compound or a Product, and other relevant scientific, technical, legal, commercial, financial, and medical factors"
  - For more certainty, consider specific diligence requirements



### **Structural Considerations-IP**

- Key provisions:
  - Definition of Intellectual Property
  - Conveyance: license vs. assignment, boundaries of agreement,
     Term
  - Collaboration—how is joint IP handled? Prosecution? Litigation?
  - License—royalty obligations and milestones, Field of Use, Territory



## Importance of IP

- ▶ IP is often a company's strongest asset
  - provides market exclusivity
  - protects the revenue stream and may provide a direct revenue source (license royalties)
  - leverage against competitors
  - furthers company goals
  - contributes to value of a company
- Risks of issues with IP diligence
  - Value of deal may decrease
  - Purchaser may ask you to fix issues, thereby delaying the deal
  - May need to negotiate with another part to fix joint ownership, license, assignment of IP, etc.
  - Purchaser may abandon deal altogether



## **Intellectual Property Diligence**

- Types of IP to be considered
  - Patents
    - Chain of title and encumbrances
    - Scope of claims, coverage of commercial embodiment, and likelihood of patentability
    - Consider validity and freedom-to-operate searches
    - Patent life left in relation to when product will hit the market
  - Trademarks
    - Protection at federal, state, or common-law
    - Ownership, current use, and licenses
    - Field of Use restrictions or coexistence agreements
  - Domain Names
  - Copyrights
    - software—assignments, licenses, goodwill
  - Trade Secrets
    - Policies in place to protect trade secrets
    - confidentiality agreements with third parties
- ▶ IP Litigation search, opinions, cease and desist letters
- IP Agreements— indemnification, representations and warranties



### **Seller Considerations of IP**

- Prepare for diligence by reviewing IP portfolio
  - Correlate patent claims with commercial embodiment, improvements, as well as potentially competitive products (blocking patents or defensive patents)
  - Understand strengths of patents (patentability, scope, covers designarounds; worldwide coverage)
  - Review issues with inventorship, ownership and license rights of IP; identify relevant documentation
  - Review software licenses and company owned code
  - Review opinions, searches, and issues directed to patentability, validity, and FTO
- Fix potential errors and oversights (clean house)
- Prepare responses for questions on IP litigation, cease & desist letters, and other IP issues
- Gather all necessary documentation
- Review your confidentiality agreements and review trade secret protocols





### **Purchaser Considerations for IP**

- Study all issued patents and prosecution histories
- Study all pending patent applications and prosecution histories
- Ask for and review results of any patentability, validity, and FTO searches
- Conduct independent searches of IP assets
- Assess patent scope, commercial embodiments, and design arounds
- Assess FTO issues
- Understand competitive landscape and ability of IP to block competitors
- Have a plan to record all IP transferred in deal in a timely manner (e.g. IP assignment documents)





## **IP Trends**

- Considerations for Small Molecules and Biologics
  - Regulatory exclusivity (e.g. NCE, CI, ODE, PED, or BLA)
  - When and how easily will generics/biosimilars come onto the market
  - Patents listable on the Orange Book (small molecules)
  - Patent term extension
- Considerations for Healthcare IT
  - Software and AI: ownership (employees, consultants) of past and future IP
  - Open source software
  - Storage of data



# **Compliance Considerations for Life Sciences Deals**

## DOJ Fraud Section Guidance February 2017

- Due Diligence Process
- Integration of Compliance in the M&A Process
- Process Connecting Due Diligence to Implementation



# **Compliance Considerations for Life Sciences Deals**

#### Due Diligence Process

- Who conducts and how accomplished?
- Self Disclosure, cooperation and individual liability

#### Some Considerations

- FCPA
- Pricing & Reimbursement
- Incentive Compensation
- Anti-Kickback
- Third Party Relationships
- Trade Secrets



# Compliance Considerations for Life Sciences Deals

Integration of Compliance in M&A Process

 "How has the compliance function been integrated into the merger, acquisition and integration process?"



# **Compliance Considerations for Life Sciences Deals**

# Process Connecting Due Diligence to Implementation

- Process for tracking and remediating misconduct or risks identified in due diligence
- Process for implementing compliance policies and procedures at new entity



# **Questions & Answers**



#### For more information, visit

# www.pepperlaw.com

Thomas M. Gallagher

gallaghert@pepperlaw.com | 215.981.4068

Jennifer L. Porter

porterj@pepperlaw.com | 215.981.4339

**Aparna Nemlekar** 

nemlekara@pepperlaw.com | 412.454.5021

